Masimo’s (MASI) “Hold” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Masimo (NASDAQ:MASI) in a research note issued to investors on Wednesday,Benzinga reports.

Other research analysts have also issued research reports about the stock. Wells Fargo & Company lifted their price target on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Piper Sandler lifted their price target on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Stifel Nicolaus restated a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Finally, Raymond James lifted their price target on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Masimo has a consensus rating of “Moderate Buy” and an average price target of $194.80.

Masimo Price Performance

Shares of NASDAQ:MASI opened at $190.34 on Wednesday. Masimo has a 12 month low of $101.61 and a 12 month high of $191.10. The stock has a market cap of $10.19 billion, a price-to-earnings ratio of 131.27 and a beta of 1.02. The stock’s 50 day moving average price is $172.56 and its 200 day moving average price is $152.84. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. The firm had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Equities research analysts anticipate that Masimo will post 4.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Masimo

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its position in Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 60 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 64 shares during the period. Blue Trust Inc. boosted its stake in shares of Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 71 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Masimo by 0.8% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider’s stock valued at $1,622,000 after buying an additional 82 shares during the period. Finally, Thrivent Financial for Lutherans boosted its stake in shares of Masimo by 0.8% during the 4th quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider’s stock valued at $1,728,000 after buying an additional 83 shares during the period. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.